Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 February 2023 - 8:01AM
Business Wire
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell
immunotherapy, leveraging its novel allogeneic Epstein-Barr virus
(EBV) T-cell platform to develop transformative therapies for
patients with cancer and autoimmune diseases, today reported the
grant of 36,750 restricted stock units of Atara’s common stock to
three newly hired employees and stock options to purchase an
aggregate of 48,300 shares of Atara’s common stock to two such
newly hired employees. These awards were approved by the
Compensation Committee of Atara’s Board of Directors and granted
under the Atara Biotherapeutics, Inc. 2018 Inducement Plan, with a
grant date of February 1, 2023, as an inducement material to the
new employee entering into employment with Atara, in accordance
with Nasdaq Listing Rule 5635(c)(4).
The restricted stock units vest over four years, with 25 percent
vesting on the first quarterly vesting date after the first
anniversary of the vesting commencement date and the remainder
vesting in 12 approximately equal quarterly installments over the
following three years, subject to the employee being continuously
employed by Atara as of such vesting dates. The stock options vest
over four years, with 25 percent vesting on the first anniversary
of the vesting commencement date for such employee and the
remainder vesting in 36 equal monthly installments over the
following three years, subject to the employee being continuously
employed by Atara as of such vesting dates. The stock options have
a ten-year term and an exercise price of $5.13, equal to the per
share closing price of Atara’s common stock as reported on February
1, 2023.
Atara is providing this information in accordance with Nasdaq
Listing Rule 5635(c)(4).
About Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. (@Atarabio) is a pioneer in T-cell
immunotherapy leveraging its novel allogeneic EBV T-cell platform
to develop transformative therapies for patients with serious
diseases including solid tumors, hematologic cancers and autoimmune
disease. With our lead program receiving marketing authorization in
Europe, Atara is the most advanced allogeneic T-cell immunotherapy
company and intends to rapidly deliver off-the-shelf treatments to
patients with high unmet medical need. Our platform leverages the
unique biology of EBV T cells and has the capability to treat a
wide range of EBV-associated diseases, or other serious diseases
through incorporation of engineered CARs (chimeric antigen
receptors) or TCRs (T-cell receptors). Atara is applying this one
platform, which does not require TCR or HLA gene editing, to create
a robust pipeline including: tab-cel for Epstein-Barr virus
positive post-transplant lymphoproliferative disease (EBV+ PTLD)
and other EBV-driven diseases; ATA188, a T-cell immunotherapy
targeting EBV antigens as a potential treatment for multiple
sclerosis; and multiple next-generation chimeric antigen receptor
T-cell (CAR-T) immunotherapies for both solid tumors and
hematologic malignancies. Improving patients’ lives is our mission
and we will never stop working to bring transformative therapies to
those in need. Atara is headquartered in Southern California. For
additional information about the company, please visit atarabio.com
and follow us on Twitter and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230203005031/en/
INVESTOR & MEDIA: Investors Eric Hyllengren
805-395-9669 ehyllengren@atarabio.com
Media Alex Chapman 805-456-4772 achapman@atarabio.com
Atara Biotherapeutics (NASDAQ:ATRA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Atara Biotherapeutics (NASDAQ:ATRA)
Historical Stock Chart
From Apr 2023 to Apr 2024